Hemostasis laboratory: Assays for platelet function and von Willebrand disease

Journal of Thrombosis and Thrombolysis

Volumn 6, Issue 2, 1998, Pages 159-167

  Kohli, Anupama ^a   Khan, Fauzia ^a   Snyder, L Michael ^a   Pechet, L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Coagulation; Hemostasis; Laboratory; Platelets; von Willebrand disease

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ARACHIDONIC ACID; BLOOD CLOTTING FACTOR 8; COLLAGEN; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; RISTOCETIN; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING; BLEEDING TIME; CARDIOPULMONARY BYPASS; CHRONIC KIDNEY FAILURE; COST EFFECTIVENESS ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMODIALYSIS; HEMOSTASIS; HUMAN; LABORATORY TEST; MYELOPROLIFERATIVE DISORDER; PARAPROTEINEMIA; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTOPATHY; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

EID: 0031763355     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008814008177     Document Type: Article

References (29)

1. Marcus AJ. Platelets and their disorders. In: Ratnoff OD, Forbes DF, eds. Disorders of Hemostasis. Philadelphia: WB Saunders, 1996:79-137.
2. Charo IF, Kieffer N, Phillips DR. Platelet membrane glycoproteins. In: Hemostasis and Thrombosis. Colman et al., eds. Philadelphia: J.B. Lippincott, 1994:489-507.
3. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
4. Weiss HJ. Inherited abnormalities of platelet granules and signal transduction. In: Colman RW, Hirsh J, Marder VJ, Saltzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3d ed. Philadelphia: JB Lippincott, 1994:673-684.
5. Rosenfeld SJ, Gralnick HR. Von Willebrand's disease In: Ratnoff OD, Forbes CD, eds. Disorders of Hemostasis. Philadelphia: WB Saunders, 1996:186-207.
6. Michelson AD. Flow cytometry: A clinical test of platelet function. Blood 1996;87:4925-4936.
7. George JN, Shatil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991; 324:27-39.
8. Mielke C, Kaneshiro M, Maher I, et al. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969;34:204-215.
9. Rosendaal FR, Sramek R, Sramek A. Is the bleeding time prolonged in oral anticoagulant treatment? Thromb Haemost 1994;71:154-155.
10. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991;77:2547-2552.
11. Nardella A, Farrell M, Pechet L, et al. Continuous improvement, quality control, and cost containment in clinical laboratory testing. Arch Pathol Lab Med 1994;118:965-968.
12. Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer - PFA-100™. Semin Thromb Hemost 1995;21(Suppl.):106-121.
13. deGroot PG. Platelet adhesion. Br J Haematol 1990;75: 308-312.
14. Salzmann EW Measurement of platelet adhesiveness: A simple in vitro technique demonstrating an abnormality in von Willebrand's disease. J Lab Clin Med 1963;62:724-735.
15. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963;168:178-195.
16. Rajasekhar D, Barnard MR, Michelson AD. Platelet hyporeactivity in very low birth weight neonates. Thromb Haemost 1997;77:1002-1007.
17. Rao AK. Congenital disorders of platelet function. Hematol Oncol Clin North Am 1990;14:65-86.
18. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 1991; 324:1716-1724.
19. Raman BKS, van Slick EJ, Riddle J, et al. Platelet function and structure in myeloproliferative diseases, myelodysplastic syndromes and secondary thrombocytosis. Am J Clin Pathol 1989;91:647-655.
20. Schafer AI. Acquired disorders of platelet function. In: Loscalzo J, Schafer AI (eds). Thrombosis and Hemorrhage. Boston: Blackwell, 1994:635-653.
21. Hirsh J, Rashke R, Warkentin TE, et al. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S-275S.
22. Sandler JE, Foster PA, George JN. Hemostasis/Platelets - Classification and Diagnosis of von Willebrand Disease. Hematology 1996 Education program, American Society of Hematology 1996:79-87.
23. Fay PJ, Smudzin TM. Topography of the human factor VIII-von Willebrand factor complex. J Biol Chem 1990;265:6197-6202.
24. Girma JP, Takahashi Y, Yoshioka A, et al. Ristocetin and Botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib. Thromb Haemost 1990;64:326-332.
25. Murdock PJ, Woodhams BJ, Matthews KB, et al. Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997;78:1272-1277.
26. Gill JC, Endres BJ, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand factor. Blood 1987;69:1691-1695.
27. Rodeghiero F, Castaman G, Dini E. Epidemiologic investigation of the prevalence of von Willebrand's disease. Blood 1987;69:454-459.
28. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997;90: 2515-2521.
29. Miller JL, Kupinski JM, Castella A, et al. von Willebrand factor binds to platelets and induces aggregation in platelettype but not type IIB von Willebrand disease. J Clin Invest 1983;72:1532-1542.